Drugs.com - Clinical Trials

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus...

Jun 3, 2025 - 06:55
 0
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn. and NEW YORK, May 31, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus...
Read More

Tags:

Previous Article

Natura &Co Targets Mexico for Comeback Growth

Next Article

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor...

Related Posts

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

May 12, 2025  0

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Hi...

May 12, 2025  0

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

May 12, 2025  0